Design: Phase 3, randomised, double-blind, placebo-controlled (SYNCHRONIZE-2)
Population: 752 adults with type 2 diabetes and BMI 27 or more; mean BMI 36.5
Primary outcome: Percent weight change and at least 5% weight loss at week 76
Effect: −8.2% (3.6 mg) and −9.8% (6.0 mg) vs −3.9% placebo; HbA1c −0.9 and −0.8 vs −0.2 points

SYNCHRONIZE-2 was a multinational, double-blind phase 3 trial of survodutide, a once-weekly agonist at both the glucagon and GLP-1 receptors. It randomised 752 adults with type 2 diabetes and a BMI of 27 or more (mean BMI 36.5, mean age about 56, baseline HbA1c 7.4%) to 3.6 mg, 6.0 mg or placebo for 76 weeks.

Under the treatment-regimen estimand, which counts everyone regardless of stopping, weight fell 8.2% on 3.6 mg and 9.8% on 6.0 mg, against 3.9% on placebo. At least 5% weight loss was reached by 57.6%, 64.5% and 35.1%. HbA1c fell 0.9 and 0.8 percentage points versus 0.2 with placebo — the higher dose did not lower glucose further.

The numbers sit in the range expected for people with diabetes, who lose less weight on incretin drugs than people without it. Gastrointestinal effects were common (73–78% on drug versus 39% on placebo), mostly mild to moderate and transient. The glucagon component is meant to add liver and energy-expenditure effects; this trial does not test those.

Survodutide is investigational and not approved by the FDA, EMA or CDSCO. For now this is a trial to know about, not a drug to prescribe.

Survodutide is investigational: not approved by FDA, EMA or CDSCO, so no prescribing decision follows yet.
Expect less weight loss with any incretin drug in people with diabetes than in obesity trials without diabetes.
The 6.0 mg dose lost more weight but did not lower HbA1c more than 3.6 mg.
Warn about gastrointestinal effects: three in four on drug reported them, mostly early and transient.
Compare it with existing agents on weight and HbA1c, not on cardiovascular outcomes, which this trial did not measure.

Why it matters

It adds a glucagon co-agonist to the incretin field, and its diabetes-trial weight loss sits below the headline numbers from non-diabetic obesity trials.

The statistics, in plain English

The placebo-adjusted weight difference is roughly 4 to 6 percentage points; the confidence intervals for each arm do not overlap placebo's, so chance is an unlikely explanation. The treatment-regimen estimand includes people who stopped the drug, so it is closer to real-world use than an on-treatment analysis.